Tumors of the Brain and Nervous System

  • Anatoliy Granov
  • Leonid Tiutin
  • Thomas Schwarz
Chapter
First Online:

Abstract

Central nervous system (CNS) tumors account for 4–5% of all oncological diseases and occur equally frequently in men and in women. These neoplasms are the third most common cause of death in the adult population. In Russia, every year four to seven cases of primary brain tumors are reported per 100,000 of the population, out of which 70% of patients die, and severe disability is observed among survivors in 30–40% of cases. In spite of improving surgical and conservative treatment methods, a reduction in the number of primary tumors is still not observed and the frequency of metastatic brain lesion cases is growing. So, over the last three decades the number of primary tumor cases has grown on average by 1.5 times, while the frequency of metastatic lesions has increased sixfold (Roelcke and Leenders 2001). Such an abrupt increase in frequency of metastatic brain lesions is due to their growing detectability owing to medical visualization methods; it is also connected with the tendency of growing survival rate among patients with extra-brain tumor localization, which simultaneously leads to more frequent brain metastases.

Keywords

Brain Tumor Radiation Necrosis Label Amino Acid Benign Meningioma Single Photon Emission Computer Tomography 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.
This is a preview of subscription content, log in to check access.

Suggested Readings

  1. Barker FG, Chang SM, Valk PE, Pounds TR, Prados MD (1997) 18Fluorodeoxyglucose uptake and survival of patients with suspected reccurent malignant glioma. Cancer 1:115–126Google Scholar
  2. Bergstrom M (1993) Positron emission tomography in tumor diagnosis and treatment follow-up. Acta Oncol 32(2):183–188PubMedGoogle Scholar
  3. Bucciero A, De Caro MI, Tedeschi E et al (1998) Atypical pleomorphic xanthoastrocytoma. J Neurosurg Sci 42(3):153–157PubMedGoogle Scholar
  4. Chen YR, Li WX, Lin YR, Chen LH (2004) Value of 18F-FDG PET imaging in diagnosing tumor resid intracranial glioma after surgery and radiotheraphy. Ai Zheng 23(10):1210–1212PubMedGoogle Scholar
  5. Di Chiro G, Brooks RA, Patronas NJ et al (1984) Issues in the in vivo measurement of glucose metabolism of human central nervous system tumours. Ann Neurol 15:S138–S146PubMedGoogle Scholar
  6. Garcia EV, Faber TL, Galt JR et al (2000) Advances in nuclear emission PET and SPECT imaging. IEEE Eng Med Biol Mag 19(5):21–33PubMedGoogle Scholar
  7. Goldman S, Levivier M, Pirotte B et al (1997) Regional methionine and glucose uptake in highe-grade gliomas: a comparative study on PET-guided stereotactic biopsy. J Nucl Med 38(9):1459–1462PubMedGoogle Scholar
  8. Gubskiy LV, Golovatenko Abram KV (1997) Difficulties and misdiagnoses in CT and MRI of brain diseases, mainly affecting the white matter. In: Abstracts of the conference on CT and MRI in multidisciplinary clinic, Moscow, 1997, pp 33–35 (in Russian)Google Scholar
  9. Heeger DJ, Ress D (2002) What does fMRI tell us about neuronal activity? Nat Rev Neurosci 3:142–151PubMedGoogle Scholar
  10. Higa T, Maetani S, Yoichiro K, Nabeshima S (2001) TI-201 SPECT compared with histopathologic grade in the prognostic assessment of cerebral gliomas. Clin Nucl Med 26(2):119–124PubMedGoogle Scholar
  11. Jacobs AH (2003) PET in gliomas. In: Schlegel U, Weller M, Westphal M (eds) Neuroonkologie. Thieme, Stuttgart, pp 72–76Google Scholar
  12. Korsakov MV (2002) Guidelines for PET radiochemistry. St. Petersburg (in Russian)Google Scholar
  13. Mankoff DA, Bellon JR (2001) Positron-emission tomographic imaging of cancer: glucose metabolism and beyond. Semin Radiat Oncol 11(1):16–27PubMedGoogle Scholar
  14. Murray RK, Granner DK, Mayes PA, Rod well VW (2000) Harpers biochemistry, 25th edn. Appleton and Lange, New YorkGoogle Scholar
  15. Phelps ME, Mazziotta JC (1985) Positron emission tomography: human brain function and biochemistry. Science 228(4701):799–809PubMedGoogle Scholar
  16. Ruhlmann J, Oehr P, Biersack HJ (1999) PET in oncology. Springer, Berlin, Heidelberg, 203ppGoogle Scholar
  17. Savchenko AYu (1997) Brain gliomas. Omsk, 312pp (in Russian)Google Scholar
  18. Tyler JL, Diksic M, Villemure J-G, Evans AC et al (1987) Metabolic and hemodynamic evaluation of gliomas using positron emission tomography. J Nucl Med 28(7):1123–1133PubMedGoogle Scholar
  19. Valk PE, Delbeke D, Bailey DL, Townsend DW, Maisey MN (2006) Positron emission tomography. Clinical practice. Springer, London, 475ppGoogle Scholar
  20. Vereshchagin NV, Bragina LK, Levin GJ et al (1986) Computed tomography of brain. Meditsina, Moscow, 246pp (in Russian)Google Scholar
  21. Zemskaya AG, Leszczynskiy BI (1985) Astrocytic brain tumor. Meditsina, Moscow (in Russian)Google Scholar

References

  1. Baba Y, Furusawa M, Murakami R et al (1997) Role of dynamic MRI in the evaluation of head and neck cancers treated with radiation therapy. J Radiol Oncol Biol Phys 37(4):783–787Google Scholar
  2. Bader JB, Samnick S, Schaefer A et al (1998) Contribution of nuclear medicine to the diagnosis of recurrent brain tumors and cerebral radionecrosis. Radiologe 38(11):924–929PubMedGoogle Scholar
  3. Bader JB, Samnick S, Moringlane JR et al (1999) Evaluation of l-3-[123I]iod-α-methyltyrozine SPET and [18F]fluorodeoxyglucose PET in the detection and grading of recurrences in patients pretreated for gliomas at follow-up: a comparative study with stereotactic biopsy. Eur J Nucl Med 26(2):144–151PubMedGoogle Scholar
  4. Benard F, Romsa J, Hustinx R (2003) Imaging gliomas with positron emission tomography and single-photon emission computed tomography. Semin Nucl Med 33:148–162PubMedGoogle Scholar
  5. Bergmann SR, Weinheimer CJ, Markham J, Herrero P (1996) Quantitation of myocardial fatty acid metabolism using PET. J Nucl Med 37(10):1723–1730PubMedGoogle Scholar
  6. Beyer T, Townsend DW (2002) Blodgett TM dual-modality PET/CT tomography for clinical oncology. J Nucl Med 46(1):24–34Google Scholar
  7. Beyer T, Watson CC, Meltzer CC et al (2001) The biograph: a premium dual-modality PET/CT tomograph for clinical oncology. Electromedica 69(2):120–126Google Scholar
  8. Black P (1993) Meningiomas. Neurosurgery 32:643–657PubMedGoogle Scholar
  9. Brunelle F (2000) Noninvasive diagnosis of brain tumours in children. Childs Nerv Syst 16(10–11):731–734PubMedGoogle Scholar
  10. Castillo M (1998) Gangliogliomas: ubiquitous or not? Am J Neuroradiol 19(5):807–809PubMedGoogle Scholar
  11. Cher LM, Murone C, Lawrentschuk N et al (2006) Correlation of hypoxic cell fraction and angiogenesis with glucose metabolic rate in gliomas using 18F-fluoromisonidazole, 18F-FDG PET and immunohistochemical studies. J Nucl Med 47:410–418PubMedGoogle Scholar
  12. Chung JK, Kim YuK, Kim SK et al (2002) Usefulness of 11C-methionine PET in the evaluation of brain lesions that are hypo- or isometabolic on 18F-FDG PET. Eur J Nucl Med 29(2):176–182Google Scholar
  13. De Reuck J, Santens P, Goethals P et al (1999) [Methyl-11 C]-thymidine positron emission tomography in tumoral and non-tumoral cerebral lesions. Acta Neurol Belg 99(2):118–125PubMedGoogle Scholar
  14. De Witte O, Levivier M, Violon Ph et al (1996) FDG-PET as a prognostic value positron emission tomography with [18F]-fluorodeoxyglucose in the low-grade from high-grade glioma. Neurosurgery 39(3):470–477PubMedGoogle Scholar
  15. De Witte O, Lefranc F, Levivier M et al (2000) FDG-PET as a prognostic factor in high-grade astrocytoma. J Neurooncol 49(2):157–163PubMedGoogle Scholar
  16. Delbeke D, Meyerowitz C, Lapidus RL et al (1995) Optimal cutoff levels of F-18-fluorodeoxyglucose uptake in the differentiation of low-grade from high-grade brain tumors with PET. Radiology 195(1):47–52PubMedGoogle Scholar
  17. Derlon JM, Chapon F, Noel MH et al (2000) Non-invasive grading of oligodendrogliomas: correlation between in vivo metabolic pattern and histopathology. Eur J Nucl Med 27(7):778–787PubMedGoogle Scholar
  18. Di Chiro G (1987) PET using FDG in brain tumors. A powerful diagnostic and prognostic tool. Invest Radiol 22(2):360–371PubMedGoogle Scholar
  19. Floeth FW, Pauleit D, Sabel M et al (2006) 18F-FET PET differentiation of ring-enhancing brain lesions. J Nucl Med 47(5):776–782PubMedGoogle Scholar
  20. Floeth FW, Pauleit D, Sabel M et al (2007) Prognostic value of O-(2-18F-fluoroethyl)-L-tyrosine PET and MRI in low-grade glioma. J Nucl Med 48:519–527PubMedGoogle Scholar
  21. Friedlander RM, Ojemann RG, Thornton AF (1999) Management of meningiomas of the cavernous sinus: conservative surgery and adjuvant therapy. Clin Neurosurg 45:279–282PubMedGoogle Scholar
  22. Ginsberg LE, Fuller GN, Hashmi M et al (1998) Significance of lack of MR contrast enhancement of supratentorial brain tumors in adults: hystopathological evaluation of a series. Surg Neurol 49:436–440PubMedGoogle Scholar
  23. Glantz MJ, Hoffman JM, Coleman RE (1991) Identification of early recurrence of primary central nervous system tumors by [18F]fluorodeoxyglucose positron emission tomography. Ann Neurol 29:347–355PubMedGoogle Scholar
  24. Gneveckow U, Jordan A, Scholz R et al (2004) Description and characterization of the novel hyperthermia- and thermoablation-system MFH 300 F for clinical magnetic fluid hyperthermia. Med Phys 31:1444–1451PubMedGoogle Scholar
  25. Groos MW, Weber WA, Feldmann HJ et al. (1998) The value of F-18-fluorodeoxyglucose PET for the 3-D-radiation treatment planning of malignant gliomas. In: Clinical investigation, Elsevier Science Inc, Marburg, pp 989–995Google Scholar
  26. Grosu AL, Weber WA, Astner ST et al (2006) 11C-methionine PET improves the target volume delineation ofr meningeomas treated with stereotactic fractionated radiotherapy. Int J Radiat Oncol Biol Phys 66:339–344PubMedGoogle Scholar
  27. Gudjonsson O, Blomquist E, Liljia A et al (2000) Evaluation of the effect of high-energy proton irradiation treatment on meningiomas by means of 11C-L-metionine PET. Eur J Nucl Med 27(12):1793–1799PubMedGoogle Scholar
  28. Hagge RJ, Wong TZ, Coleman RE (2001) Positron emission tomography: brain tumors and lung cancer. Radiol Clin North Am 39(5):871–881PubMedGoogle Scholar
  29. Hanakawa K, Ikeda H, Ishii K et al (1998) High uptake on 11-C methionine PET scan in the pituitary gland of a patient with cerebral glioma after surgical abortion. No To Shinkei 50(6):573–577PubMedGoogle Scholar
  30. Henze M, Schuhmacher J, Hipp P et al (2001) PET imaging of somatostatin receptors using [68GA]-DOTA-D-Phe1-Tyr3-octreotide: first results in patients with meningiomas. J Nucl Med 42:1053–1056PubMedGoogle Scholar
  31. Herholz K, Pietrzyk U, Voges J et al (1993) Correlation of glucose consumption and tumor cell density in astrocytomas. A stereotactic PET study. J Neurosurg 79:853–858PubMedGoogle Scholar
  32. Hustinx R, Alavi A (1999) SPECT and PET imaging of brain tumors. Neuroimaging Clin N Am 9(4):751–766PubMedGoogle Scholar
  33. Imahori Y, Ueda S, Ohmori Y et al (1998) Fluorine-18-labeled fluoroboronophenylalanine PET in patients with glioma. J Nucl Med 39(2):325–333PubMedGoogle Scholar
  34. Iwai Y, YamanaKa K, Oda J et al (2001) Tracer accumulation in radiation necrosis of the brain after thallium-201 SPECT and [11C]methionine PET-case report. Neurol Med Chir 41(8):415–418Google Scholar
  35. Jager PL, Vaalburg W, Pruim J et al (2001) Radiolabeled amino acids: basic aspects and clinical applications in oncology. J Nucl Med 42(3):432–445PubMedGoogle Scholar
  36. Jonson SD, Welch MJ (2002) Invastigations into tumor accumulation and peroxisome proliferator activated receptor binding by F-18 and C-11 fatty acids. Nucl Med Biol 29(2):211–216PubMedGoogle Scholar
  37. Kleihues P, Burger PC, Scheithauer BW (1993) The new WHO classification of brain tumours. Brain Pathol 3(2):255–268PubMedGoogle Scholar
  38. Konovalov AN, Kornienko VN, Pronin IN (1997) Magnetic resonance imaging in neurosurgery. WIdar, Moscow, 472pp (in Russian)Google Scholar
  39. Kornienko VN, Pronin IN (2006) Diagnostic neurooncology. Andreeva T, Moscow, 1326pp (in Russian)Google Scholar
  40. Kostenikov NA, Fadeev NP, Tyutin LA, Savello VE, Ryzhkova DV (2002) Comparative evaluation of the diagnostic possibilities of PET with 18F-FDG and 11C-sodium butyrate in brain formations and acute cerebrovascular diseases (the results of semiquantitative data analysis). Vestn Rentgenol Radiol 4:4–8 (in Russian)PubMedGoogle Scholar
  41. Kostenikov NA, Fadeev NP, Tyutin LA (2006) The possibility of positron emission tomography with a new radiopharmaceutical 11C- sodium butyrate in neurooncology. Med Radiol Bezopasnost 6:13–23 (in Russian)Google Scholar
  42. Krayevskiy NA, Smolyannikova AV, Sarkisov DS (1982) Pathoanatomical diagnosis of human tumors. Meditsina, Moscow, 511pp (in Russian)Google Scholar
  43. Lacic M, Maisey MN, Kusic Z (1997) Positron emission tomography in oncology: the most sophisticated imaging technology. Acta Med Croatica 51(1):1–9PubMedGoogle Scholar
  44. Langen KJ, Hamacher K, Weckesser M et al (2006) O-(2-[18F] fluoroethyl)-L-tyrosine: uptake mechanisms and clinical application. Nucl Med Biol 33:287–294PubMedGoogle Scholar
  45. Larcos G, Maisey MN (1996) FDG-PET screening for cerebral metastases in patients with suspected malignancy. Nucl Med Commun 17:197–198PubMedGoogle Scholar
  46. Leeds NE, Jackson EF (1994) Current imaging techniques for the evaluation of brain neoplasms. Curr Opin Oncol 6:254–261PubMedGoogle Scholar
  47. Levivier M, Goldman S, Pirotte B et al (1995) Diagnostic yield of stereotactic brain biopsy guided by positron emission tomography with [18F]fluorodeoxyglucose. J Neurosurg 82:445–452PubMedGoogle Scholar
  48. Lüdemann L, Warmuth C, Plotkin M et al (2009) Brain tumor perfusion: Comparison of dynamic contrast enhanced magnetic resonance imaging using T(1), T(2), and T(2)(*) contrast, pulsed arterial spin labeling, and H(2)(15)O positron emission tomography. Eur J Radiol 70(3):465–474PubMedGoogle Scholar
  49. Mantle RE, Lach B, Delgado MR et al (1999) Predicting the probability of meningioma recurrence based on the quantity of peritumoral brain edema on computerized tomography scanning. J Neurosurg 91:375–383PubMedGoogle Scholar
  50. Martinez-Mata AM, Martinez-Pardavila R, de Arriba-Villamor C, Espinosa-Mogro H (1999) Cerebral gliomatosis with development of multifocal glioblastoma. Rev Neurol 28(8):781–783PubMedGoogle Scholar
  51. Medvedev SV, Behtereva NP, Kostenikov NA et al (1996) Positron emission tomography in the diagnosis of brain formations. Zh Vopr Neirokhir Im N N Burdenko 1:21–26 (in Russian)PubMedGoogle Scholar
  52. Meyer GJ, Spetzger U, Mueller H et al (2000) A positron emission tomography case report: high F-18-fluorodeoxyglucose uptake in low-grade supratentorial ganglioglioma. Clin Nucl Med 25(9):694–697PubMedGoogle Scholar
  53. Meyer PT, Schreckenberger M, Spetzger U et al (2001) Comparison of visual and ROI-based brain tumour grading using 18F-FDG PET: ROC analyses. Eur J Nucl Med 28(2):165–174PubMedGoogle Scholar
  54. Moulin-Romsée G, D’Hondt E, de Groot T, Goffin J et al (2007) Non-invasive grading of brain tumours using dynamic amino acid PET imaging: does it work for 11C-methionine? Eur J Nucl Med Mol Imaging 12:2082–2087Google Scholar
  55. Muhr C, Gudjonsson O, Lilja A et al (2001) Meningioma treated with interferon-alpha, evaluated with [(11)C]-L-methionine positron emission tomography. Clin Cancer Res 7:2269–2276PubMedGoogle Scholar
  56. Nuutinen J, Sonninen P, Lehikoinen P et al (2000) Radiotherapy treatment planning and long-term follow-up with [11-C]-methionine PET in patients with low-grade astrocytoma. Int J Radiat Oncol Biol Phys 48(1):43–52PubMedGoogle Scholar
  57. Ogawa T, Inugami A, Hatazawa J et al (1996) Clinical positron emission tomography for brain tumors: comparison of fludeoxyglucose, F-18 and L-methyl-11C-methionine. AJNR Am J Neuroradiol 17:345–353PubMedGoogle Scholar
  58. Otte A (1999) Cerebral deafferentiation in operated gliomas as a predictor for malignancy? Eur J Nucl Med 26(11):1523PubMedGoogle Scholar
  59. Padma MV, Said S, Jacobs M et al (2003) Prediction of pathology and survival by FDG PET in gliomas. J Neurooncol 64(3):227–237PubMedGoogle Scholar
  60. Pauleit D, Floeth F, Hamacher K et al (2005) O-(2-[18F]fluoroethyl)-L-tyrosine PET combined with MRI improves the diagnostic assessment of cerebral gliomas. Brain 128:678–687PubMedGoogle Scholar
  61. Paulus W, Peiffer J (1989) Intratumoral histologic heterogeneity of gliomas. A quantitative study. Cancer 64:442–447PubMedGoogle Scholar
  62. Piepmeier JM (1987) Observations in the current treatment of low-grade astrocytic tumors of cerebral hemispheres. J Neurosurg 67(2):177–188PubMedGoogle Scholar
  63. Pietrzyk U, Herholz K, Fink G et al (1994) An interactive technique for three-dimentional image registration: validation for PET, SPECT, MRI and CT brain studies. J Nucl Med 35:2011–2018PubMedGoogle Scholar
  64. Pirotte B, Goldman S, Massager N et al (2004) Combined use of 18F-fluorodeoxyglucose and 11C-methionine in 45 positron emission tomography-guided stereotactic brain biopsies. J Neurosurg 101:476–483PubMedGoogle Scholar
  65. Plotkin M, Eisenacher J, Bruhn H et al (2004) 123I-IMT SPECT and 1H-MR-spectroscopy at 3.0 Tesla in the differential diagnosis of recurrent or residual gliomas: a comparative study. J Neuro Oncol 70:49–58Google Scholar
  66. Plotkin M, Amthauer H, Eisenacher J et al (2005) Value of 123I-IMT SPECT for diagnosis of recurrent non-astrocytic intracranial tumours. Neuroradiology 47:18–26PubMedGoogle Scholar
  67. Plotkin M, Gneveckow U, Meier-Hauff K et al (2006) 18F-FET PET for planning of thermotherapy using magnetic nanoparticles in recurrent glioblastomas. Int J Hyperthermia 22:319–325PubMedGoogle Scholar
  68. Plotkin M, Denecke T, Michel R et al (2007) Value of Ga-68-DOTATOC PET/CT for planning the radiotherapy in meningiomas. J Nucl Med 48(Suppl 2):32Google Scholar
  69. Pöpperl G, Götz C, Gildehaus FJ et al (2002) Initial experiences with adjuvant locoregional radioimmunotherapy using 131I-labeled monoclonal antibodies against tenascin (BC-4) for treatment of glioma (WHO III and IV). Nuklearmedizin 41:120–128PubMedGoogle Scholar
  70. Pöpperl G, Gotz C, Rachinger W et al (2004) Value of O-(2-[18F]fluoroethyl)-L-tyrosine PET for the diagnosis of recurrent glioma. Eur J Nucl Med Mol Imaging 31:1464–1470PubMedGoogle Scholar
  71. Pöpperl G, Götz C, Rachinger W et al (2006a) Serial O-(2-[18F]-fluoroethyl)-L-tyrosine PET for monitoring the effects of intracavitary radioimmunotherapy in patients with malignant glioma. Eur J Nucl Med Mol Imaging 33:792–800PubMedGoogle Scholar
  72. Pöpperl G, Kreth FW, Herms J et al (2006b) Analysis of 18F-FET PET for grading of recurrent gliomas: is evaluation of uptake kinetics superior to standard methods? Nucl Med 47:393–403Google Scholar
  73. Rachinger W, Goetz C, Popperl G et al (2005) Positron emission tomography with O-(2-[18F]fluoroethyl)-l-tyrosine versus magnetic resonance imaging in the diagnosis of recurrent gliomas. Neurosurgery 57:505–511PubMedGoogle Scholar
  74. Ribom D, Eriksson A, Hartman M et al (2001) Positron emission tomography 11C-methionine and survival in patients with low-grade gliomas. Cancer 92(6):1541–1549PubMedGoogle Scholar
  75. Ribom D, Engler H, Blomquist E, Smits A (2002) Potential significance of 11C-methionine PET as a marker for the radiosensitivity of low-grade gliomas. Eur J Nucl Med 29(5):632–640Google Scholar
  76. Ringel F, Cedzich C, Schramm J (2007) Microsurgical technique and results of a series of 63 spheno-orbital meningiomas. Neurosurgery 60(Suppl 4):214–221PubMedGoogle Scholar
  77. Roelcke U, Leenders KL (2001) PET in neurooncology. J Cancer Res Clin Oncol 127(1):2–8PubMedGoogle Scholar
  78. Roessler K, Gatterbauer B, Becherer A et al (2007) Surgical target selection in cerebral glioma surgery: linking methionine (MET) PET image fusion and neuronavigation. Minim Invasive Neurosurg 50:273–280PubMedGoogle Scholar
  79. Sadeghi N, Salmon I, Decaestecker C et al (2007) Stereotactic comparison among cerebral blood volume, methionine uptake, and histopathology in brain glioma. AJNR Am J Neuroradiol 28:455–461PubMedGoogle Scholar
  80. Saga T, Kawashima H, Araki N et al (2006) Evaluation of primary brain tumors with FLT-PET: usefulness and limitations. Clin Nucl Med 12:774–780Google Scholar
  81. Sasaki M, Ichiya Y, Kuwabara Y et al (1996) Hyperperfusion and hypermetabolism in brain radiation necrosis with epileptic activity. J Nucl Med 37:1174–1176PubMedGoogle Scholar
  82. Schwarz A, Kuwert T (2000) Nuclear medicine diagnosis in diseases of the central nervous system. Radiologe 40(10):858–862PubMedGoogle Scholar
  83. Seemann MD (2005) Whole-body PET/MRI: the future in oncological imaging. Technol Cancer Res Treat 4:577–582PubMedGoogle Scholar
  84. Sergeev PV, Polyaev YuA, Yudin AL, Szimanowskiy NL (2007) Contrast media. Izvestiya, Moscow, 496pp (in Russian)Google Scholar
  85. Skvortsova Tlu, Brodskaya ZL, Rudas MS et al (2001a) Comparative evaluation of different radiopharmaceuticals in the PET diagnosis of brain tumors. Med Visualisation 1:67–74 (in Russian)Google Scholar
  86. Skvortsova Tlu, Rudas MS, Brodskaya ZL et al (2001b) New criteria in positron emission tomography with 11C-methionine for diagnosis of brain gliomas. Zh Vopr Neirokhir Im N N Burdenko 2:12–16 (in Russian)PubMedGoogle Scholar
  87. Spaeth N, Wyss MT, Weber B et al (2004) Uptake of 18F-fluorocholine, 18F-fluoroethyl-l-tyrosine, and of cerebral gliomas. 18F-FDG in acute cerebral radiation injury in the rat: implications for separation of radiation necrosis from tumor recurrence. J Nucl Med 45:1931–1938PubMedGoogle Scholar
  88. Spence MM, Muzi M, Graham MM et al (2002) 2-[18F]Fluoro-2-deoxyglucose and glucose uptake in malignant gliomas before and after radiotherapy. Clin Cancer Res 8:971–979PubMedGoogle Scholar
  89. Spence A, Mankoff DA, Muzi M (2003) Positron emission tomography imaging of brain tumors. Neuroimaging Clin N Am 13:717–739PubMedGoogle Scholar
  90. Stafford SL, Perry A, Suman VJ, Meyer FB, Scheithauer BW, Lohse CM, Shaw EG (1998) Primarily resected meningiomas: out-come and prognostic factors in 581 Mayo Clinic patients, 1978 through 1988. Mayo Clin Proc 73:936–942PubMedGoogle Scholar
  91. Steinling M (1997) SPECT and PET in neurological practice. Acta Neurol Belg 97(3):163–167PubMedGoogle Scholar
  92. Stöber B, Tanase U, Herz M et al (2006) Differentiation of tumour and inflammation: characterisation of [methyl-3H]methionine (MET) and O-(2-[18F] fluoroethyl)-L-tyrosine (FET) uptake in human tumour and inflammatory cells. Eur J Nucl Med Mol Imaging 33:932–939PubMedGoogle Scholar
  93. Stockhammer F, Thomale UW, Plotkin M et al (2007) 18F-fluorodeoxyglucose uptake is associated with 1p and 19q loss in WHO grade II gliomas. J Neurosurg 106:633–637PubMedGoogle Scholar
  94. Stockhammer F, Plotkin M, Amthauer H, van Landeghem KH, Woiciechowsky C (2008) Correlation of F-18-fluoro-ethyl-tyrosin uptake with vascular and cell density in non-contrast-enhancing gliomas. J Neurooncol 88(2):205–210PubMedGoogle Scholar
  95. Tsuyuguchi N, Sunada I, Iwai Y et al (2003) Methionine positron emission tomography of recurrent metastatic brain tumor and radiation necrosis after stereotactic radiosurgery: is a differential diagnosis possible? J Neurosurg 98:1056–1064PubMedGoogle Scholar
  96. Vaquero J, Zurita M, Coca S et al (2000) Prognostic significance of clinical and angiogenesis-related factors in low-grade oligodendrogliomas. Surg Neurol 54:229–234PubMedGoogle Scholar
  97. Villringer K, Jäger H, Dichgans M et al (1995) Differential diagnosis of CNS lesions in AIDS patients by FDG-PET. J Comput Assist Tomogr 19:532–536PubMedGoogle Scholar
  98. Walker MD, Strike TA, Sheline GE (1979) An analysis of dose-effect relationship in the radiotherapy of malignant gliomas. Int J Radiat Oncol Biol Phys 5:1725–1731PubMedGoogle Scholar
  99. Walker C, du Plessis DG, Fildes D et al (2004) Correlation of molecular genetics with molecular and morphological imaging in gliomas with an oligodendroglial component. Clin Cancer Res 10:7182–7191PubMedGoogle Scholar
  100. Weber WA, Wester HJ, Anca L et al (2000) O-(2[18F]Fluoroethyl)-L-tyrosine and L-[methyl-11C]methionine uptake in brain tumors: initial results of a comparative study. Eur J Nucl Med 27(5):542–549PubMedGoogle Scholar
  101. Wester HJ, Herz M, Weber W et al (1999) Synthesis and radiopharmacology of O-(2-[18F]-fluoroethyl)-L-tyrosine for tumor imaging. J Nucl Med 40:205–212PubMedGoogle Scholar
  102. Wieder H, Schwaiger M, Weber W (2003) C-11 methionine PET targets brain lesions. Diagn Imaging Eur 19(3):43–45Google Scholar
  103. Wong TZ, van der Westhuizen GJ, Coleman RE (2002) Positron emission tomography imaging of brain tumors. Neuroimaging Clin N Am 12:615–626PubMedGoogle Scholar
  104. Wurm R, Plotkin M (2008) Rolle der PET und PET/CT in der Planung der stereotaktischen Strahlentherapie. Der Nuklearmediziner 31:29–32Google Scholar
  105. Yamada N, Imakita S, Sakuma T et al (1996) Intracranial calcification on gradient echo phase image: depiction of diamagnetic susceptibility. Radiology 198:171–178PubMedGoogle Scholar
  106. Yamada T, Maruoka S, Yamada S, Sonobe M (1999) Comparison of 201Tl-SPECT and MRI using Gd-DTPA for glioma. Nippon Igaku Hoshasen Gakkai Zasshi 59(8):402–408PubMedGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2013

Authors and Affiliations

  • Anatoliy Granov
    • 1
  • Leonid Tiutin
    • 2
  • Thomas Schwarz
    • 3
  1. 1.Russian Research Center for Radiology and SurgerySt. PetersburgRussia
  2. 2.Department of Radiology and Nuclear MedicineRussian Research Center for RadiologySt. PetersburgRussia
  3. 3.Department of Nuclear Medicine Division of RadiologyMedical University GrazGrazAustria

Personalised recommendations